Summary of Key Points Core Viewpoint - The company announced the cancellation of certain fundraising special accounts, reallocating the remaining funds to supplement its working capital permanently, following the completion of specific investment projects [1][3][4]. Fundraising Overview - The company was approved by the China Securities Regulatory Commission to issue 17 million shares at a price of 14.71 yuan per share, raising a total of 250,070,000 yuan, with the actual net amount being confirmed through an audit report [1][2]. Fund Management and Usage - To ensure proper management and usage of the raised funds, the company established special accounts and signed tripartite/quadripartite supervision agreements with its underwriter and the banks holding the funds [2][3]. - The company has implemented a fundraising management system to regulate the storage, usage, and management of the funds, ensuring compliance with relevant regulations [1][2]. Cancellation of Fundraising Accounts - The company decided to cancel two fundraising special accounts at Shanghai Pudong Development Bank due to the completion of the related investment project and the decision to permanently supplement the remaining funds into working capital [3][4]. - The cancellation of these accounts also leads to the termination of the corresponding tripartite/quadripartite supervision agreements [4].

Core Viewpoint - Awei Technology has experienced a decline in profitability despite its growth in the in vitro diagnostic field since its listing on June 16, 2021, with a market value decrease from 26.04 billion yuan to 14.23 billion yuan over four years [1][3][5] Business Overview - Awei Technology's main business includes the research, production, sales, and service of medical clinical testing analysis instruments and supporting in vitro diagnostic reagents and medical consumables [3] - The core product revenue structure shows that reagents account for the highest proportion at 53.44%, followed by instruments at 25.17% [3] Financial Performance - In 2021, Awei Technology achieved a net profit attributable to shareholders of 0.31 billion yuan, which decreased to 0.23 billion yuan by the end of the latest complete fiscal year in 2024, reflecting a cumulative profit growth decline of 26.97% [3] - The company has not reported any annual losses in the past four years, with profit growth occurring in three out of four years, representing a 75.0% success rate [3] - Revenue remained relatively stable, with 2.11 billion yuan in 2021 and 2.03 billion yuan in 2024, indicating a lack of growth momentum [3] Market Capitalization - Awei Technology reached a market capitalization peak of 30.94 billion yuan and a stock price of 45.5 yuan on June 16, 2021, but as of June 13, the market cap has decreased to 14.23 billion yuan, resulting in a market value loss of 16.71 billion yuan, or 54.02% [5]

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 证券代码：688067 证券简称：爱威科技 公告编号：2025-020 爱威科技股份有限公司 第五届监事会第三次会议决议公告 （一）审议通过《关于公司使用暂时闲置自有资金进行现金管理的议案》 议案内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于使用暂时闲置自有资金进行现金管理的公告》。 监事会认为：在确保正常经营所需资金及资金安全的前提下，公司本次使 用暂时闲置自有资金进行现金管理，有利于提高公司闲置自有资金利用率，增 加公司收益和股东回报，不存在损害公司及全体股东，特别是中小股东利益的 情形。综上，监事会同意公司本次使用暂时闲置自有资金进行现金管理事项。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 爱威科技股份有限公司监事会 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第五 届监事会第三次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议由 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-021 爱威科技股份有限公司 关于使用暂时闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日分别召开 第五届董事会第三次会议和第五届监事会第三次会议，审议通过《关于公司使 用暂时闲置自有资金进行现金管理的议案》，同意公司使用额度不超过 35,000 万元（含本数）的暂时闲置自有资金进行现金管理，自董事会审议通过之日起 12 个月内有效，在上述额度及决议有效期内，资金可以循环滚动使用。公司董 事会授权公司管理层在上述有效期和额度范围内行使该事项决策权并签署相关 合同文件，具体事项由公司财务部负责组织实施。现将相关情况公告如下： 一、本次使用闲置自有资金进行现金管理的基本情况 (一) 投资目的 在确保不影响自有资金安全和正常生产经营的前提下，公司拟使用暂时闲 置自有资金进行现金管理, 以提高公司资金使用效率，增加公司现金资产收益， 为公司及股东获取更多回报。 （ ...

第五届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688067 证券简称：爱威科技 公告编号：2025-020 爱威科技股份有限公司 2025 年 5 月 30 日 1 一、监事会召开情况 爱威科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第五 届监事会第三次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议由 监事会主席段小霞女士主持，以现场方式召开。本次会议的通知、召开及审议 程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司使用暂时闲置自有资金进行现金管理的议案》 议案内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于使用暂时闲置自有资金进行现金管理的公告》。 监事会认为：在确保正常经营所需资金及资金安全的前提下，公司本次使 用暂时闲置自有资金进行现金管理，有利于提高公司闲置自有资金利用率，增 加公司收益和股东回报，不存在损害公 ...

Core Viewpoint - The company aims to enhance its AI capabilities and product offerings while maintaining a strong focus on technological innovation and efficiency improvements in its operations [1][2]. Group 1: Company Strategy and Innovation - The company is committed to deepening its research in AI and expanding its product matrix, with a focus on technology innovation mechanisms [1]. - The company has accumulated a vast database of desensitized data based on real specimen images, which is a core resource that is difficult for competitors to replicate [2]. - In 2024, the company participated in the development of four group standards and authored four academic works, further solidifying its technological leadership [2]. Group 2: Financial Performance - In a challenging environment for the medical device industry, the company achieved growth in both revenue and net profit in 2024, demonstrating strong operational resilience [2]. - The company implemented cost-reduction and efficiency-enhancement measures across procurement, manufacturing, and R&D, leading to a decrease in product costs [2]. - The sales proportion of high-margin reagents and consumables has gradually increased, resulting in an overall improvement in gross margin compared to the previous year [2]. Group 3: Market Expansion and Product Development - The company has installed its testing instruments in over 6,000 hospitals nationwide, with nearly 8,000 units in use, which supports the growth of high-margin reagent sales [3]. - The company has launched multiple POCT product series covering various health areas, and these products are being sold through various channels including e-commerce platforms and clinics [3]. - The company is actively building third-party IVD laboratories and developing a smart healthcare platform aimed at serving grassroots markets [4].

证券代码：688067 证券简称：爱威科技 公告编号：2025-019 爱威科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 23 日 （二） 股东大会召开的地点：湖南省长沙市岳麓区学士街道茯苓路 26 号公司 319 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 19 | | --- | --- | | 普通股股东人数 | 19 | | 2、出席会议的股东所持有的表决权数量 | 35,118,629 | | 普通股股东所持有表决权数量 | 35,118,629 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.1992 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.1992 | （四 ...

湖南启元律师事务所 二〇二五年五月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410005 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号 世茂环球金融中心 63 层 410005 Tel：(0731) 8295 3778 Fax：(0731) 8295 3779 http://www.qiyuan.com 湖南启元律师事务所 关于爱威科技股份有限公司 2024 年年度股东大会的法律意见书 致：爱威科技股份有限公司 关于 爱威科技股份有限公司 2024年年度股东大会的 法律意见书 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托书 等； 湖南启元律师事务所（以下简称"本所"）接受爱威科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司 2024 年年度股东大会（以下 简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员资 格、表决程序和表决结果的合法有效性进行现场律师见证，并 ...

Core Viewpoint - The company is focused on expanding its AI image recognition technology applications in various medical testing fields, aiming to become a comprehensive service provider in medical laboratory equipment and related products [2][3]. Company Development and Technology - The company has diversified its product line in the medical testing instrument sector and is applying its core technology to blood, body fluid, pathology, and microbiological testing [2]. - The company has established a competitive advantage in the automation of clinical specimen microscopic examination, having entered this technology field early and developed a leading medical microscopic image database [4][5]. Industry Outlook - The high-end medical device industry is expected to have broad development prospects driven by national import substitution policies, technological innovation, and globalization strategies [3]. - The integration of artificial intelligence technology with modern diagnostic medicine is anticipated to accelerate the shift towards intelligent diagnostics in various fields [12]. Financial Performance - In 2024, the company achieved a net profit of 22.84 million yuan, a year-on-year increase of 6.07%, with a significant increase in net profit excluding non-recurring gains of 24.99% [10]. - For Q1 2025, the company reported a net profit of 6.32 million yuan, up 24.63% year-on-year, and a net profit of 5.01 million yuan after excluding non-recurring gains, reflecting a 48.77% increase [10][13]. Market Strategy - The company plans to maintain continuous R&D investment and product updates to sustain its competitive edge in the industry [8]. - Future growth drivers include expanding into new customer segments, particularly in grassroots and civilian markets, as well as international markets [8]. Product Applications - The company is leveraging machine vision and deep learning technologies to automate the analysis of microscopic components in clinical specimens, significantly improving accuracy and efficiency [5]. - The company is also exploring applications of its technology in non-medical fields such as aquatic biological detection and mineral testing [9].

爱威科技股份有限公司 2024 年年度股东大会会议资料 爱威科技股份有限公司 2024年年度股东大会会议资料 二〇二五年五月 爱威科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024年年度股东大会会议须知 1 | | --- | | 2024年年度股东大会会议议程 3 | | 议案一：《关于公司<2024年度董事会工作报告>的议案》 5 | | 议案二：《关于公司<2024年度监事会工作报告>的议案》 10 | | 议案三：《关于公司<2024年度财务决算报告>的议案》 13 | | 议案四：《关于公司2024年年度报告及其摘要的议案》 17 | | 议案五：《关于公司2024年度利润分配方案的议案》 18 | | 议案六：《关于公司2025年中期分红安排的议案》 20 | | 议案七：《关于续聘公司2025年度审计机构的议案》 21 | | 议案八：《关于公司2025年度董事薪酬的议案》 22 | | 议案九：《关于公司2025年度监事薪酬的议案》 23 | | 议案十：《关于公司募集资金投资项目变更、结项及延期并将节余募集资金永久 | | 补充流动资金的议案》…… … 24 | | 听 ...